GLPwatch

MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.

Diabetes · 2018

Last updated 2026-05-28

In human pancreatic cells, a protein called MondoA responds to high blood sugar by moving into the cell nucleus and turning on genes like TXNIP, which is linked to diabetes. However, drugs that mimic GLP-1, such as Exendin-4, can block this process and reduce the activity of these genes. When MondoA is silenced, cells take up more glucose.

AI summary of the abstract below.

JournalDiabetes, 2018
Citations35
Relative citation ratio1.28
NIH percentile59
Molecules
Conditions studied Type 2 Diabetes

Abstract

Although the mechanisms by which glucose regulates insulin secretion from pancreatic β-cells are now well described, the way glucose modulates gene expression in such cells needs more understanding. Here, we demonstrate that MondoA, but not its paralog carbohydrate-responsive element-binding protein, is the predominant glucose-responsive transcription factor in human pancreatic β-EndoC-βH1 cells and in human islets. In high-glucose conditions, MondoA shuttles to the nucleus where it is required for the induction of the glucose-responsive genes arrestin domain-containing protein 4 (ARRDC4) and thioredoxin interacting protein (TXNIP), the latter being a protein strongly linked to β-cell dysfunction and diabetes. Importantly, increasing cAMP signaling in human β-cells, using forskolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the shuttling of MondoA and potently inhibits TXNIP and ARRDC4 expression. Furthermore, we demonstrate that silencing MondoA expression improves glucose uptake in EndoC-βH1 cells. These results highlight MondoA as a novel target in β-cells that coordinates transcriptional response to elevated glucose levels.

Verbatim abstract via PubMed 29282201 ↗